E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Academic Article

Overview

authors

Bewersdorf, Jan Philipp

Stahl, Maximilian

Chandhok, Namrata Sonia

Derkach, Andriy

Wysocki, Mateusz

Bourcier, Jessie

Totiger, Tulasigeri M

Abdel-wahab, Omar
Stein, Eytan M

publication date

October 9, 2023

published in

Leukemia Journal

Research

keywords

Neoplasms

Identity

Digital Object Identifier (DOI)

10.1038/s41375-023-02050-4

PubMed ID

37814121